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Abstract
Background: Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the
patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage
DDIs. The study objective was to determine the prevalence of DDIs involving study medications in subjects enrolling in
National Clinical Trials Network (NCTN) clinical trials at a single institution. DDIs were evaluated based on study protocol
recommendations for concomitant medication use (i.e. exclude, avoid or use caution), screening via DDI tool, and
pharmacist review.
Methods: Subjects enrolled in NCTN trials of commercially available agents between January 2013 and August 2017
were included if a complete medication list was available. Complete medication lists were collected from the date of
enrollment or the next available date then screened utilizing protocol guidance and the DDI screening tool, Lexicomp®
Drug Interactions (Wolters Kluwer, Hudson, OH). Interactions were reviewed for clinical relevance: defined as a DDI that
would require a medication change to ensure study agent safety and efficacy at enrollment.
Results: One hundred and twenty-eight subjects enrolled in 35 clinical trials were included. Protocol guidance detected
15 unique DDI pairs that should be avoided or used with caution in 10.2% (13/128) of subjects. The majority of these
subjects did not have a clinically relevant DDI (69.2%, 9/13) based on pharmacist review. Lexicomp® detected moderate
to major DDIs in 24.2% (31/128) of subjects, with 9.4% (12/128) having a clinically relevant DDI.
Conclusions: This study confirms a high prevalence of DDIs present in subjects enrolling in oncology clinical
trials. Further efforts should be made to improve methods to detect and manage DDIs in patients enrolling
on clinical trials to ensure patient safety and trial data validity.
Keywords: Oncology clinical trial drug interaction
Background
Clinically significant drug-drug interactions (DDIs)
occur when one drug impacts the efficacy or safety of
another drug taken concomitantly. Both drug and pa-
tient characteristics contribute to the risk for DDI.
Drugs that are dependent on a single metabolic pathway
(i.e. CYP3A4) and those that induce or inhibit com-
monly used metabolizing enzymes, such as CYP450, are
more likely to cause DDI [1]. Additional mechanisms of
DDIs include inhibition or induction of transporters,
such as P-glycoprotein (P-gp), competitive protein bind-
ing, or modification of gastric acid leading to changes in
medication absorption [2]. DDIs can also occur when
two drugs taken together have opposing mechanisms of
action (i.e. antihypertensive and stimulant), similar thera-
peutic effects (i.e. additive anticoagulation) or overlapping
side effect profiles (i.e. QT prolongation, CNS depression,
or immunosuppression) [3]. Many anti-cancer medica-
tions that are taken to prolong life have the potential to
cause severe toxicity, consequently, small differences in
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drug concentration can determine which of these effects a
patient experiences [1]. This makes it is critically import-
ant to identify and resolve potential DDI in oncology pa-
tients [2, 4]. In addition to medication characteristics,
patient factors can also make DDI more likely to occur.
Elderly patients comprise the majority of cancer diagnoses
[5] increasing the likelihood of concomitant disease states
managed by medications. Consequently, cancer patients
have high rates of polypharmacy, which increases occur-
rence of DDI [6].
Despite standard DDI screening procedures, including
pharmacist review of medication orders prior to dispens-
ing and availability of DDI screening tools [7], clinically
relevant DDIs are found in 16–41% of oncology patients
[8–11]. This high prevalence suggests current DDI
screening processes in oncology clinical care are sub-
optimal. This situation is likely even worse in oncology
clinical trial subjects, for whom standard DDI proce-
dures and tools do not exist. While systematic,
pharmacist-conducted DDI screening for oncology clin-
ical trial enrollment would be ideal [12], we have re-
cently reported that many cancer centers do not
systematically conduct DDI screening and that pharma-
cists are rarely involved, with DDI screening instead be-
ing the responsibility of clinical research coordinators or
research nurses [13]. These individuals, who often lack
DDI screening expertise [14, 15], rely primarily on DDI
information contained in trial protocols.
The identification and management of DDIs for oncol-
ogy clinical trial subjects is especially important because
in addition to the impact of DDI on treatment safety
and efficacy, DDI can also affect the accuracy and valid-
ity of data collected within the clinical trial. DDI could
impact data validity by causing increased adverse out-
comes due to added toxicity or decreased efficacy if
study medication concentrations are impacted. Minimal
research has been conducted to determine the preva-
lence of DDI in oncology clinical trial subjects to deter-
mine whether current DDI screening practices are
sufficient.
National Clinical Trials Network (NCTN) clinical tri-
als typically use commercially available oncology agents
making it an ideal patient population to study based on
the availability of DDI information. The objective of this
study was to determine the prevalence of DDI involving
study medications in subjects enrolled on NCTN clinical
trials at the University of Michigan (U-M) Rogel Cancer
Center. DDI were evaluated based on the study proto-
col’s recommendations for concomitant medication use
(i.e. exclude, avoid, or use caution) and, separately,
screening via a DDI tool (Lexicomp® Online, Wolters
Kluwer, Hudson, OH). DDI identified using either tech-
nique were then manually assessed for clinical relevance
by a pharmacist.
Methods
Protocol selection and patient data collection
All NCTN protocols of commercially available oncology
agents (phase II through IV trials) that were open be-
tween January 2013 and August 2017 at the cancer cen-
ter were included. Two protocols included medications
that were approved during the trial, and subjects were
excluded if they were enrolled prior to approval. Sub-
jects were included if their complete medication lists on
the date of enrollment or within one month of enroll-
ment were available in the electronic medical record.
Complete medication lists from each subject were re-
corded from the day of enrollment or the next available
date. This study was granted exemption by the Univer-
sity of Michigan IRB.
Protocol guided DDI screening
Protocols were reviewed for any guidance on DDIs that
indicated the medication combination would cause trial
exclusion or suggested the combination should be
avoided or used with caution. Medication lists were
screened for DDIs as defined by each respective
protocol.
Lexicomp® guided DDI screening
Medication lists were screened for major/contraindi-
cated (level D or X) DDIs involving the study agent
using Lexicomp® Drug Interactions. Lexicomp® was
chosen based on our previous work examining DDI
screening tool abilities to detect clinically relevant DDI
[7]. Study medications were examined for the following
medication characteristics based on the DDI mecha-
nisms identified: P-gp transport, CYP450 metabolism,
inhibition or induction, QT prolongation, CNS depres-
sion, protein binding, immunosuppression, anticoagula-
tion and pH dependent absorption.
DDI identification by pharmacist review
DDIs identified by the protocol guidance or Lexicomp®
were reviewed by two individuals, a pharmacist and a
Doctor of Pharmacy student, for clinical relevance. Clin-
ical relevance was defined as a DDI that, in their judge-
ment, would warrant a medication change prior to
enrollment to ensure drug safety and/or efficacy based
on currently available evidence (i.e. journal articles, FDA
package inserts). Discordant decisions were discussed
until consensus was reached.
Protocol guidance assessment for identified clinically
relevant DDI
Protocols were reviewed retrospectively for guidance re-
garding all clinically relevant DDI to determine the pro-
portion of clinically relevant DDI for which there is no
guidance in the clinical trial protocol.
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Statistical analysis
Descriptive statistics were calculated to determine the
prevalence of DDI based on protocol guidance (exclude,
avoid, and use with caution) or Lexicomp® (level D or X)
and the rates of clinically relevant DDIs based on
pharmacist review. The prevalence of clinically relevant
DDI was also stratified by DDI mechanism (i.e. CYP450
metabolism, P-gp transport, pH dependent absorption,
QT prolongation). Mechanisms were not included in the
stratification if no clinically relevant interactions were
found (i.e. anticoagulation, protein binding, immunosup-
pression, CNS depression). Additionally, the proportion
of clinically relevant DDIs that impacted toxicity or effi-
cacy of the study agent, as opposed to a concomitant
medication, was determined. An independent samples
t-test was performed to compare the number of con-
comitant medications taken by subjects who did and did
not have a clinically relevant DDI, based on pharmacist
review. IBM® SPSS® Statistics (v24) software was used for
the statistical analysis.
Results
Enrolled subject characteristics
One hundred and twenty-eight patients were included in
the analysis (Fig. 1) from 35 NTCN protocols including
mostly monoclonal antibodies and protein kinase inhibi-
tors (Additional file 1). Ten subjects were not included
because a complete medication list was not available.
Enrolled subjects were taking an average of 6.8 concomi-
tant medications (standard deviation: 4.77).
DDIs detected by Lexicomp®
Lexicomp® detected 43 DDIs in 31 (24.2%) subjects with
a range of 0–3 DDIs per patient. Pharmacist review of
the clinical relevance of DDI detected by Lexicomp iden-
tified 10 unique DDI pairs, which occurred 13 times in
Fig. 1 Flow diagram indicating patient exclusion criteria. Protocols were included if they exclusively used medications that were commercially
available, however, patients were excluded if they were enrolled prior to FDA approval of the agents (n = 2, 1.4%). Patients were excluded if a
complete medication list was not available at or around the time of enrollment (n = 10, 7.1%)
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12 (9.4%) unique patients (Table 1). Only one subject
had two clinically relevant DDIs. Subjects with a clinic-
ally relevant DDI were taking a greater mean number of
concomitant medications than those without a clinically
relevant DDI (9.33 vs. 6.50, 95% CI: 0.006 to 5.661, p =
0.05). Of the 12 patients with clinically relevant DDIs,
the efficacy or toxicity of the study agent was affected in
five subjects (41.7%, 5/12, Fig. 2).
The most prevalent medication characteristic was
CYP450 metabolism, and 7.1% (7/98) of subjects receiv-
ing a study agent that had CYP450 DDI potential had a
clinically relevant DDI (Table 2). All of the clinically
relevant DDI with CYP450 DDI potential were through
CYP3A4.
DDIs detected by protocol guidance
The majority of protocols (26/35, 74.3%) included guid-
ance to exclude, avoid or use concomitant medications
with caution. Seven protocols included guidance to use a
concomitant medication with caution (7/35, 20.0%), 17
included DDI to avoid (17/35, 48.6%), and 16 included
DDI that would exclude a subject from enrollment (16/
35, 45.7%). Based on protocol guidance, 17 total DDIs
were detected in 13 (10.2%) patients with a range of 0–2
DDIs per subject (Fig. 3). No patients were taking medi-
cations that were considered protocol exclusion criteria,
13 (10.2%) subjects were taking medications that were
suggested by the protocols to be avoided if possible or
used with caution. Of the 15 unique DDI pairs detected
based on protocol guidance, 3 (20.0%) interactions were
considered clinically relevant based on the pharmacist
review (Table 1) and occurred in 4 subjects (3.1%). Of
the subjects with clinically relevant DDI, all of the DDI
would have impacted the efficacy or toxicity of the study
agent.
Retrospective assessment of protocol guidance for
clinically relevant DDI
Of the 10 DDI determined to be clinically relevant by
pharmacist review, 3 (30%) were suggested to avoid in
the study protocols. The remaining 7 (70%) were not
mentioned in the protocols; none of the 10 clinically
relevant DDIs were considered exclusion criteria in the
protocols.
Discussion
Oncology patients are at a higher risk of DDI due to
their high rates of polypharmacy [6] and the sensitivity
of efficacy and toxicity to small changes in the concen-
tration of anti-cancer drugs [1]. Although DDI risk has
been assessed in oncology patients, it has not been ex-
tensively examined in clinical trial subjects. It is ex-
tremely important in this population to manage DDI
because they not only impact subject safety and efficacy
but also trial data accuracy. The objective of this study
was to determine the proportion of subjects enrolling in
NCTN trials at the U-M Rogel Cancer Center with DDI
detected based on protocol guidance, Lexicomp® screen-
ing, and manual pharmacist review.
Screening by protocol guidance identified DDIs in
10.2% of patients and Lexicomp® identified major or
contraindicated DDI in 24.2% of subjects. Only one prior
retrospective DDI study has been conducted in oncology
trial subjects to the authors’ knowledge. Phase I oncol-
ogy clinical trial subjects were examined for CYP450
DDIs prior to and after enrollment. Prior to enrollment,
69% of subjects had at least one DDI with the study
agent [16]. The majority (85%) of these DDI were re-
solved during screening by discontinuing or switching
the interacting medications, while the remaining 15%,
which were not listed as exclusion criteria in the proto-
col, were unresolved after enrollment [16]. Similarly,
none of the clinically relevant DDIs identified in subjects
enrolled on NCTN trials in our analysis were considered
exclusions to enrollment.
The prevalence identified in our study (9.4–24.2%) is on
the lower end of DDI rates found in oncology patients
(16–41%) [8–11]. The higher DDI rates in some studies
could be attributed to inclusion of DDIs between con-
comitant medications or supportive care agents in
addition to DDI with anticancer agents or inclusion of less
severe DDI [10, 11]. The finding that subjects with a clin-
ically relevant DDI were taking a greater number of con-
comitant medications (6.50 vs. 9.33) is consistent with
previous reports that oncology patients taking more con-
comitant medications have higher rates of DDI [6, 8].
Not all DDIs identified by protocol guidance or Lexi-
comp® would have posed an immediate risk to the sub-
ject. After examining the DDIs flagged by protocol
guidance and Lexicomp® for clinical relevance, 9.4% of
subjects in this study had an DDI that, in our judge-
ment, would have required immediate action at enroll-
ment to ensure patient safety or efficacy. About half of
these DDIs would have impacted efficacy or toxicity of
the study agent, which, in addition to its importance in
ensuring optimal treatment outcomes for the subject,
would also affect the accuracy and validity of the clinical
trial data. The majority of identified DDI can be easily
resolved by dose changes [17], increased monitoring
(e.g. QT prolongation) [18], or a medication change [19],
and would not warrant trial exclusion.
Only 20.0% of the DDI pairs identified based on proto-
col guidance were considered clinically relevant. Add-
itionally, 70.0% of the clinically relevant DDI pairs were
not identified by the protocols suggesting that protocol
guidance may not be optimally calibrated for DDI
screening. Pharmacist screening is standard of care in
clinical practice, and pharmacist conducted medication
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reviews would be ideal for trial enrollment [12]. How-
ever, pharmacists are not always available and are not
typically involved in screening of clinical trial subjects
[13]. The frequency of clinically relevant DDI in subjects
enrolled on NCTN trials indicates improvements can be
made to reduce DDI. Possible solutions include improv-
ing protocol guidance to encompass more clinically rele-
vant DDI and improving the DDI screening process to
ensure oncology clinical trial subject safety, efficacy, and
data accuracy.
Table 1 Interactions Detected by Protocol Guidance and Lexicomp® Including Their Mechanism of Interaction and Clinical Relevance
Study Agent(s) Interacting Drug (n with interaction) Protocol Guidance Lexicomp® Clinically Relevanta Interaction Mechanism
everolimus carvedilol (2) Avoid yes yes P-gp
dasatinib antacids (1) Avoid yes yes pH
vemurafenib ondansetron (1) Avoid yes yes QT
dabrafenib amlodipine (2) Avoid yes no CYP450
vemurafenib venlafaxine (1) Avoid yes no QT
cabozantinib ondansetron (1) Avoid no no QT
ipilimumab, nivolumab ondansetron (2) Avoid no no QT
dabrafenib omeprazoleb (1) Caution yes no pH
dabrafenib atorvastatin (1) Caution yes no CYP450
dabrafenib omeprazolec (1) Caution yes no CYP450
olaparib cetirizine (1) Caution no no P-gp
olaparib ranitidine (1) Caution no no P-gp
testosterone dabigatran (1) Caution no no anticoagulation
trametinib duloxetine (1) Caution no no protein binding
trametinib olanzapine (1) Caution no no protein binding
enzalutamide amlodipine (2) None yes yes CYP450
enzalutamide citalopram (1) None yes yes CYP450
enzalutamide diltiazem (1) None yes yes CYP450
enzalutamide omeprazole (1) None yes yes CYP450
enzalutamide tramadol (2) None yes yes CYP450
enzalutamide venlafaxine (1) None yes yes CYP450
crizotinib escitalopram (1) None yes yes QT
dabrafenib tamsulosin (1) None yes no CYP450
enzalutamide alprazolam (1) None yes no CYP450
enzalutamide hydrocodone (1) None yes no CYP450
enzalutamide modafinil (1) None yes no CYP450
enzalutamide ondansetron (2) None yes no CYP450
enzalutamide tamsulosin (1) None yes no CYP450
dexamethasone echinacea (1) None yes no immunosuppression
pomalidomide echinacea (1) None yes no immunosuppression
pomalidomide hydrocodone (3) None yes no CNS depression
pomalidomide oxycodone (2) None yes no CNS depression
pomalidomide tramadol (4) None yes no CNS depression
crizotinib granisetron (1) None yes no QT
vemurafenib albuterol (1) None yes no QT
dexamethasone antacids (3) None yes no unknown
P-gp P-glycoprotein
aClinical relevance was determined by study team review and defined as a drug-drug interaction that would require a medication change to ensure study agent
safety/efficacy at enrollment
bdabrafenib as victim and omeprazole as perpetrator
comeprazole as victim and dabrafenib as perpetrator
Marcath et al. BMC Cancer         (2018) 18:1155 Page 5 of 8
Currently there are DDI screening tools available for
clinical practice, but none have been developed for clin-
ical trial enrollment. DDI screening tools available for
use in clinical practice are not ideally suited for use in
oncology clinical trial screening. These tools only in-
clude commercially available agents, often contain tech-
nical language, and identify DDI between all drugs a
patient is on [20, 21]. A DDI screening tool that includes
investigational agents, provides alerts using language
suited for multiple levels of health care providers, only
identifies DDIs involving the study agent, and filters
medication characteristics based on protocol guidance
would be optimal for DDI screening in oncology clinical
trials.
This retrospective analysis was not able to deter-
mine whether any DDI were detected and resolved
during screening, therefore, we have limited ability to
assess the frequency or effectiveness of DDI screening
within our cancer center. Additionally, the clinical
outcome of the DDI was not assessed in this cohort,
and it is unknow if the detect DDI caused adverse
patient outcomes. It is possible that medication lists
were not completely accurate, although it is standard
procedure at U-M to update medication lists at the
start of all patient visits. Also, a standardized ap-
proach was taken to determine which DDIs were clin-
ically relevant; however, if a different pharmacist
reviewed the DDIs, our results would likely have
Fig. 2 Breakdown of Lexicomp® detected drug-drug interactions by patient and their clinical relevance. Patients were screened for major
and contraindicated drug-drug interactions with Lexicomp® Drug Interactions. The major and contraindicated interactions detected were
examined for clinical relevance by patient, and then further examined if they would impact study agent efficacy or toxicity. A total of
3.9% patients (n = 5) had clinically relevant interactions that could impact the study agent efficacy or toxicity in addition to validity of
study data. DDI = drug-drug interaction
Table 2 Number of Clinically Relevant Interactions Stratified by Medication Characteristics
Medication Characteristic Total patients on protocol with characteristic Clinically relevanta interactions with characteristic (%)
CYP450 metabolism 98 7 (7.1%)
P-glycoprotein transport 69 2 (2.9%)
QT prolongation 23 2 (8.7%)
pH dependent absorption 6 1 (16.7%)
aClinical relevance was determined by study team review and defined as a drug-drug interaction that would require a medication change to ensure study
medication safety/efficacy at enrollment
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changed slightly. Finally, this study was a convenience
sample conducted only at the University of Michigan
Rogel Cancer Center for NCTN trials with a small
number of subjects and these findings might not be
generalizable to other institutions or non-NCTN on-
cology trials.
Conclusion
This study indicates a high prevalence of clinically
relevant DDI in subjects enrolling on NCTN clinical
trials. Further efforts should be made to detect and
manage DDI, potentially through improvements in
protocol guidance, pharmacist involvement in screen-
ing, and development of a clinical trial-specific DDI
screening tool. Further research is needed to confirm
that identifying clinically relevant DDI and resolving
them prior to clinical trial enrollment would improve
patient outcomes and ensure validity of data collected
within clinical trials.
Additional file
Additional file 1: Protocol medications by class. The included protocol
medications listed by medication class. (DOCX 14 kb)
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